Healio: PRESERVED-HF: Dapagliflozin improves HFpEF symptoms at 12 weeks

Dapagliflozin improved symptoms and physical limitations in patients with heart failure (HF) with preserved ejection fraction, according to results from the PRESERVED-HF trial.

"The treatment effect was large, clinically meaningful and statistically significant," Mikhail Kosiborod, MD, FACC, FAHA, cardiologist at Saint Luke's Mid America Heart Institute and professor of medicine at University of Missouri-Kansas City School of Medicine, said during a presentation at the Heart Failure Society of America Annual Scientific Meeting. He noted the results were consistent regardless of diabetes status and ejection fraction.  

Read the full Healio article: PRESERVED-HF: Dapagliflozin improves HFpEF symptoms at 12 weeks

Related Content

Sep. 15, 2021

TCTMD: PRESERVED-HF: Dapagliflozin Improves Symptoms, Physical Limitations in HFpEF
Dapagliflozin eases symptoms and physical limitations among patients who have heart failure with preserved ejection fraction (HFpEF) within a relatively short time period.
Sep. 15, 2021

Cardiovascular Business: Dapagliflozin significantly improves HFpEF symptoms
Treatment with dapagliflozin improves the symptoms of patients with heart failure with preserved ejection fraction (HFpEF), according to new findings presented at the Heart Failure Society of America's Annual Scientific Meeting.
Saint Luke's Mid America Heart Institute
Oct. 28, 2021

PRESERVED-HF trial findings on the substantial impact of dapagliflozin in individuals with heart failure with preserved ejection fraction (HFpEF) published in Nature Medicine
The findings of the PRESERVED-HF trial, offering potential new hope for people struggling with heart failure with preserved ejection fraction (HFpEF), are published in the journal, Nature Medicine.